-
1
-
-
0037565623
-
Pharmacogenetics of oral anticoagulants
-
1:CAS:528:DC%2BD3sXksVWks78%3D 12724615
-
Daly AK, King BP. Pharmacogenetics of oral anticoagulants. Pharmacogenetics. 2003;13(5):247-52.
-
(2003)
Pharmacogenetics
, vol.13
, Issue.5
, pp. 247-252
-
-
Daly, A.K.1
King, B.P.2
-
2
-
-
65249129769
-
Effect of age on stroke prevention therapy in patients with atrial fibrillation: The atrial fibrillation investigators
-
van Walraven C, Hart RG, Connolly S, Austin PC, Mant J, Hobbs FD, Koudstaal PJ, Petersen P, Perez-Gomez F, Knottnerus JA, et al. Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators. Stroke J Cereb Circ. 2009;40(4):1410-6.
-
(2009)
Stroke J Cereb Circ
, vol.40
, Issue.4
, pp. 1410-1416
-
-
Van Walraven, C.1
Hart, R.G.2
Connolly, S.3
Austin, P.C.4
Mant, J.5
Hobbs, F.D.6
Koudstaal, P.J.7
Petersen, P.8
Perez-Gomez, F.9
Knottnerus, J.A.10
-
3
-
-
59649117935
-
The largest prospective warfarin-treated cohort supports genetic forecasting
-
1:CAS:528:DC%2BD1MXhtlGhsbc%3D 18574025 2630264
-
Wadelius M, Chen LY, Lindh JD, Eriksson N, Ghori MJ, Bumpstead S, Holm L, McGinnis R, Rane A, Deloukas P. The largest prospective warfarin-treated cohort supports genetic forecasting. Blood. 2009;113(4):784-92.
-
(2009)
Blood
, vol.113
, Issue.4
, pp. 784-792
-
-
Wadelius, M.1
Chen, L.Y.2
Lindh, J.D.3
Eriksson, N.4
Ghori, M.J.5
Bumpstead, S.6
Holm, L.7
McGinnis, R.8
Rane, A.9
Deloukas, P.10
-
4
-
-
31344451857
-
Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans
-
1:CAS:528:DC%2BD28Xls1Gksg%3D%3D
-
Takahashi H, Wilkinson GR, Nutescu EA, Morita T, Ritchie MD, Scordo MG, Pengo V, Barban M, Padrini R, Ieiri I, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genom. 2006;16(2):101-10.
-
(2006)
Pharmacogenet Genom
, vol.16
, Issue.2
, pp. 101-110
-
-
Takahashi, H.1
Wilkinson, G.R.2
Nutescu, E.A.3
Morita, T.4
Ritchie, M.D.5
Scordo, M.G.6
Pengo, V.7
Barban, M.8
Padrini, R.9
Ieiri, I.10
-
5
-
-
33745567198
-
Long-term, secondary treatment of deep venous thrombosis: Do we know the appropriate duration of treatment or therapeutic regimen?
-
15341702
-
Ansell J. Long-term, secondary treatment of deep venous thrombosis: do we know the appropriate duration of treatment or therapeutic regimen? Curr Hematol Rep. 2004;3(5):355-6.
-
(2004)
Curr Hematol Rep
, vol.3
, Issue.5
, pp. 355-356
-
-
Ansell, J.1
-
6
-
-
33845500310
-
Safety indicators for inpatient and outpatient oral anticoagulant care: [Corrected] Recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency
-
1:STN:280:DC%2BD2s%2FisVGhsA%3D%3D 17116128
-
Baglin TP, Cousins D, Keeling DM, Perry DJ, Watson HG. Safety indicators for inpatient and outpatient oral anticoagulant care: [corrected] Recommendations from the British Committee for Standards in Haematology and National Patient Safety Agency. Br J Haematol. 2007;136(1):26-9.
-
(2007)
Br J Haematol
, vol.136
, Issue.1
, pp. 26-29
-
-
Baglin, T.P.1
Cousins, D.2
Keeling, D.M.3
Perry, D.J.4
Watson, H.G.5
-
7
-
-
0036785249
-
Patient-specific factors predictive of warfarin dosage requirements
-
12243598
-
Absher RK, Moore ME, Parker MH. Patient-specific factors predictive of warfarin dosage requirements. Ann Pharmacother. 2002;36(10):1512-7.
-
(2002)
Ann Pharmacother
, vol.36
, Issue.10
, pp. 1512-1517
-
-
Absher, R.K.1
Moore, M.E.2
Parker, M.H.3
-
8
-
-
21144448879
-
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose
-
1:CAS:528:DC%2BD2MXksl2ltrk%3D 15930419
-
Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, McLeod HL, Blough DK, Thummel KE, Veenstra DL, Rettie AE. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med. 2005;352(22):2285-93.
-
(2005)
N Engl J Med
, vol.352
, Issue.22
, pp. 2285-2293
-
-
Rieder, M.J.1
Reiner, A.P.2
Gage, B.F.3
Nickerson, D.A.4
Eby, C.S.5
McLeod, H.L.6
Blough, D.K.7
Thummel, K.E.8
Veenstra, D.L.9
Rettie, A.E.10
-
9
-
-
77954508907
-
CYP4F2 rs2108622: A minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement
-
1:CAS:528:DC%2BC3cXhtVOmsrfO 20653676 2911553
-
Cen HJ, Zeng WT, Leng XY, Huang M, Chen X, Li JL, Huang ZY, Bi HC, Wang XD, He YL, et al. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. Br J Clin Pharmacol. 2010;70(2):234-40.
-
(2010)
Br J Clin Pharmacol
, vol.70
, Issue.2
, pp. 234-240
-
-
Cen, H.J.1
Zeng, W.T.2
Leng, X.Y.3
Huang, M.4
Chen, X.5
Li, J.L.6
Huang, Z.Y.7
Bi, H.C.8
Wang, X.D.9
He, Y.L.10
-
10
-
-
0034872136
-
Pharmacogenetics of warfarin elimination and its clinical implications
-
1:CAS:528:DC%2BD3MXmsl2gsb4%3D 11523725
-
Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet. 2001;40(8):587-603.
-
(2001)
Clin Pharmacokinet
, vol.40
, Issue.8
, pp. 587-603
-
-
Takahashi, H.1
Echizen, H.2
-
11
-
-
25844438367
-
The Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension
-
1:CAS:528:DC%2BD2MXhtVymsrfE 16202848
-
Dreisbach AW, Japa S, Sigel A, Parenti MB, Hess AE, Srinouanprachanh SL, Rettie AE, Kim H, Farin FM, Hamm LL, et al. The Prevalence of CYP2C8, 2C9, 2J2, and soluble epoxide hydrolase polymorphisms in African Americans with hypertension. Am J Hypertens. 2005;18(10):1276-81.
-
(2005)
Am J Hypertens
, vol.18
, Issue.10
, pp. 1276-1281
-
-
Dreisbach, A.W.1
Japa, S.2
Sigel, A.3
Parenti, M.B.4
Hess, A.E.5
Srinouanprachanh, S.L.6
Rettie, A.E.7
Kim, H.8
Farin, F.M.9
Hamm, L.L.10
-
12
-
-
33646205301
-
Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals
-
1:CAS:528:DC%2BD28XlvVenu74%3D 16646575
-
Garcia-Martin E, Martinez C, Ladero JM, Agundez JA. Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther. 2006;10(1):29-40.
-
(2006)
Mol Diagn Ther
, vol.10
, Issue.1
, pp. 29-40
-
-
Garcia-Martin, E.1
Martinez, C.2
Ladero, J.M.3
Agundez, J.A.4
-
13
-
-
27744485315
-
A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data
-
1:CAS:528:DC%2BD2MXhtFeisLjP
-
Hillman MA, Wilke RA, Yale SH, Vidaillet HJ, Caldwell MD, Glurich I, Berg RL, Schmelzer J, Burmester JK. A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. Clinl Med Res. 2005;3(3):137-45.
-
(2005)
Clinl Med Res
, vol.3
, Issue.3
, pp. 137-145
-
-
Hillman, M.A.1
Wilke, R.A.2
Yale, S.H.3
Vidaillet, H.J.4
Caldwell, M.D.5
Glurich, I.6
Berg, R.L.7
Schmelzer, J.8
Burmester, J.K.9
-
14
-
-
39449086981
-
CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: A prospective randomized controlled study
-
1:CAS:528:DC%2BD1cXitlGnsbs%3D 17851566
-
Caraco Y, Blotnick S, Muszkat M. CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther. 2008;83(3):460-70.
-
(2008)
Clin Pharmacol Ther
, vol.83
, Issue.3
, pp. 460-470
-
-
Caraco, Y.1
Blotnick, S.2
Muszkat, M.3
-
15
-
-
63449117825
-
A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose
-
19300499 2652833
-
Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, Whittaker P, Ranganath V, Kumanduri V, McLaren W, et al. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet. 2009;5(3):e1000433.
-
(2009)
PLoS Genet
, vol.5
, Issue.3
, pp. e1000433
-
-
Takeuchi, F.1
McGinnis, R.2
Bourgeois, S.3
Barnes, C.4
Eriksson, N.5
Soranzo, N.6
Whittaker, P.7
Ranganath, V.8
Kumanduri, V.9
McLaren, W.10
-
16
-
-
34547138943
-
Evaluation of genetic factors for warfarin dose prediction
-
1:CAS:528:DC%2BD2sXhtFClu7vL 17456829 1855340
-
Caldwell MD, Berg RL, Zhang KQ, Glurich I, Schmelzer JR, Yale SH, Vidaillet HJ, Burmester JK. Evaluation of genetic factors for warfarin dose prediction. Clin Med Res. 2007;5(1):8-16.
-
(2007)
Clin Med Res
, vol.5
, Issue.1
, pp. 8-16
-
-
Caldwell, M.D.1
Berg, R.L.2
Zhang, K.Q.3
Glurich, I.4
Schmelzer, J.R.5
Yale, S.H.6
Vidaillet, H.J.7
Burmester, J.K.8
-
17
-
-
77952927473
-
Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups
-
1:CAS:528:DC%2BC3cXmsFSnt7g%3D 20504253 2904527
-
Scott SA, Khasawneh R, Peter I, Kornreich R, Desnick RJ. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics. 2010;11(6):781-91.
-
(2010)
Pharmacogenomics
, vol.11
, Issue.6
, pp. 781-791
-
-
Scott, S.A.1
Khasawneh, R.2
Peter, I.3
Kornreich, R.4
Desnick, R.J.5
-
18
-
-
23044440450
-
The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: Proposal for a new dosing regimen
-
1:CAS:528:DC%2BD2MXhtVKqt7%2FL 15947090
-
Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, King BP, Wood P, Kesteven P, Daly AK, Kamali F. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005;106(7):2329-33.
-
(2005)
Blood
, vol.106
, Issue.7
, pp. 2329-2333
-
-
Sconce, E.A.1
Khan, T.I.2
Wynne, H.A.3
Avery, P.4
Monkhouse, L.5
King, B.P.6
Wood, P.7
Kesteven, P.8
Daly, A.K.9
Kamali, F.10
-
19
-
-
60849097257
-
Estimation of the warfarin dose with clinical and pharmacogenetic data
-
1:STN:280:DC%2BD1M7ls1Smuw%3D%3D 19228618
-
Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009;360(8):753-64.
-
(2009)
N Engl J Med
, vol.360
, Issue.8
, pp. 753-764
-
-
Klein, T.E.1
Altman, R.B.2
Eriksson, N.3
Gage, B.F.4
Kimmel, S.E.5
Lee, M.T.6
Limdi, N.A.7
Page, D.8
Roden, D.M.9
Wagner, M.J.10
-
20
-
-
34248525060
-
HIV-infected African Americans are willing to participate in HIV treatment trials
-
17351837 1824784
-
Garber M, Hanusa BH, Switzer GE, Mellors J, Arnold RM. HIV-infected African Americans are willing to participate in HIV treatment trials. J Gen Intern Med. 2007;22(1):17-42.
-
(2007)
J Gen Intern Med
, vol.22
, Issue.1
, pp. 17-42
-
-
Garber, M.1
Hanusa, B.H.2
Switzer, G.E.3
Mellors, J.4
Arnold, R.M.5
-
21
-
-
34547658151
-
Effect of patient-specific factors on weekly warfarin dose
-
1:CAS:528:DC%2BD2sXps1CqtrY%3D 18488070 2386352
-
Whitley HP, Fermo JD, Chumney EC, Brzezinski WA. Effect of patient-specific factors on weekly warfarin dose. Ther Clin Risk Manag. 2007;3(3):499-504.
-
(2007)
Ther Clin Risk Manag
, vol.3
, Issue.3
, pp. 499-504
-
-
Whitley, H.P.1
Fermo, J.D.2
Chumney, E.C.3
Brzezinski, W.A.4
-
22
-
-
0036434235
-
Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population
-
1:CAS:528:DC%2BD38Xps1Olsbs%3D 12445031 1874480
-
Burian M, Grosch S, Tegeder I, Geisslinger G. Validation of a new fluorogenic real-time PCR assay for detection of CYP2C9 allelic variants and CYP2C9 allelic distribution in a German population. Br J Clin Pharmacol. 2002;54(5):518-21.
-
(2002)
Br J Clin Pharmacol
, vol.54
, Issue.5
, pp. 518-521
-
-
Burian, M.1
Grosch, S.2
Tegeder, I.3
Geisslinger, G.4
-
23
-
-
64149111606
-
Rapid single-nucleotide polymorphism detection of cytochrome P450 (CYP2C9) and Vitamin K epoxide reductase (VKORC1) genes for the warfarin dose adjustment by the SMart-amplification process version 2
-
1:CAS:528:DC%2BD1MXktVWqsbg%3D 19181737
-
Aomori T, Yamamoto K, Oguchi-Katayama A, Kawai Y, Ishidao T, Mitani Y, Kogo Y, Lezhava A, Fujita Y, Obayashi K, et al. Rapid single-nucleotide polymorphism detection of cytochrome P450 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genes for the warfarin dose adjustment by the SMart-amplification process version 2. Clin Chem. 2009;55(4):804-12.
-
(2009)
Clin Chem
, vol.55
, Issue.4
, pp. 804-812
-
-
Aomori, T.1
Yamamoto, K.2
Oguchi-Katayama, A.3
Kawai, Y.4
Ishidao, T.5
Mitani, Y.6
Kogo, Y.7
Lezhava, A.8
Fujita, Y.9
Obayashi, K.10
-
24
-
-
73149102765
-
Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population
-
19954515 3224726
-
Kudzi W, Dodoo AN, Mills JJ. Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population. BMC Med Genet. 2009;10:124.
-
(2009)
BMC Med Genet
, vol.10
, pp. 124
-
-
Kudzi, W.1
Dodoo, A.N.2
Mills, J.J.3
-
25
-
-
0344512432
-
Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations
-
1:CAS:528:DC%2BD2cXivFSmsA%3D%3D 14616425 1884305
-
Allabi AC, Gala JL, Desager JP, Heusterspreute M, Horsmans Y. Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br J Clin Pharmacol. 2003;56(6):653-7.
-
(2003)
Br J Clin Pharmacol
, vol.56
, Issue.6
, pp. 653-657
-
-
Allabi, A.C.1
Gala, J.L.2
Desager, J.P.3
Heusterspreute, M.4
Horsmans, Y.5
-
26
-
-
79959411039
-
Combined CYP2C9, VKORC1 and CYP4F2 frequencies among Amerindians, Mozambicans and Brazilians
-
1:CAS:528:DC%2BC3MXnvVakurw%3D 21692610
-
Vargens DD, Damasceno A, Petzl-Erler ML, Suarez-Kurtz G. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among Amerindians, Mozambicans and Brazilians. Pharmacogenomics. 2011;12(6):769-72.
-
(2011)
Pharmacogenomics
, vol.12
, Issue.6
, pp. 769-772
-
-
Vargens, D.D.1
Damasceno, A.2
Petzl-Erler, M.L.3
Suarez-Kurtz, G.4
-
27
-
-
70649111382
-
CYP2C9∗8 is prevalent among African-Americans: Implications for pharmacogenetic dosing
-
1:CAS:528:DC%2BD1MXpslOmu7g%3D 19663669 2737687
-
Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ. CYP2C9∗8 is prevalent among African-Americans: implications for pharmacogenetic dosing. Pharmacogenomics. 2009;10(8):1243-55.
-
(2009)
Pharmacogenomics
, vol.10
, Issue.8
, pp. 1243-1255
-
-
Scott, S.A.1
Jaremko, M.2
Lubitz, S.A.3
Kornreich, R.4
Halperin, J.L.5
Desnick, R.J.6
-
28
-
-
40749123052
-
Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations
-
1:CAS:528:DC%2BD1cXit1Sisrk%3D 18252229 2427171
-
Scott SA, Edelmann L, Kornreich R, Desnick RJ. Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet. 2008;82(2):495-500.
-
(2008)
Am J Hum Genet
, vol.82
, Issue.2
, pp. 495-500
-
-
Scott, S.A.1
Edelmann, L.2
Kornreich, R.3
Desnick, R.J.4
-
29
-
-
62349134303
-
Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: A prospective study in Chinese patients
-
1:CAS:528:DC%2BD1MXjsVWqsbk%3D
-
Huang SW, Chen HS, Wang XQ, Huang L, Xu DL, Hu XJ, Huang ZH, He Y, Chen KM, Xiang DK, et al. Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenet Genom. 2009;19(3):226-34.
-
(2009)
Pharmacogenet Genom
, vol.19
, Issue.3
, pp. 226-234
-
-
Huang, S.W.1
Chen, H.S.2
Wang, X.Q.3
Huang, L.4
Xu, D.L.5
Hu, X.J.6
Huang, Z.H.7
He, Y.8
Chen, K.M.9
Xiang, D.K.10
|